"10.1371_journal.pone.0072059","plos one","2013-08-26T00:00:00Z","Claudia Duehrkop; Yara Banz; Rolf Spirig; Sylvia Miescher; Marc W Nolte; Martin Spycher; Richard A G Smith; Steven H Sacks; Robert Rieben","Department of Clinical Research, University of Bern, Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland; Institute of Pathology, University of Bern, Bern, Switzerland; CSL Behring AG, Bern, Switzerland; CSL Behring GmbH, Marburg, Germany; MRC Centre for Transplantation, Division of Transplantation Immunology and Mucosal Biology, King's College London School of Medicine at Guy's, London, United Kingdom","Conceived and designed the experiments: CD RS SM MWN MS RR. Performed the experiments: CD. Analyzed the data: CD. Wrote the paper: CD RR. Performed histological assessment: YB. Provided APT070 and critically evaluated complement-related data: RAGS SHS.","The authors have the following interests. Rolf Spirig, Sylvia Miescher and Martin Spycher are employees of CSL Behring AG, and Marc W. Nolte of CSL Behring GmbH. Claudia Dührkop was paid in part by grant of CSL Behring AG. Robert Rieben received grant support from CSL Behring AG. Steven H. Sacks and Richard A. G. Smith are publicly associated with APT070. C1 esterase inhibitor (Berinert®) as well as the vehicle (10 mg/ml glycine, 2.9 mg/ml sodium citrate, 8.5 mg/ml sodium chloride, pH 7.0) were provided by CSL Behring (CSL Behring GmbH, Marburg, Germany). There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","08","Claudia Duehrkop","CD",9,TRUE,6,1,1,2,TRUE,TRUE,FALSE,0,NA,FALSE
